[go: up one dir, main page]

MX2007006524A - Metodos para el suministro dirigido de material genetico al higado. - Google Patents

Metodos para el suministro dirigido de material genetico al higado.

Info

Publication number
MX2007006524A
MX2007006524A MX2007006524A MX2007006524A MX2007006524A MX 2007006524 A MX2007006524 A MX 2007006524A MX 2007006524 A MX2007006524 A MX 2007006524A MX 2007006524 A MX2007006524 A MX 2007006524A MX 2007006524 A MX2007006524 A MX 2007006524A
Authority
MX
Mexico
Prior art keywords
methods
gene therapy
liver
genetic material
target organ
Prior art date
Application number
MX2007006524A
Other languages
English (en)
Inventor
Ronald K Scheule
Bradley L Hodges
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2007006524A publication Critical patent/MX2007006524A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

La presente invencion proporciona metodos para la administracion mejorada de varios agentes terapeuticos, tales como agentes para la terapia genica, a la vasculatura de un organo diana en un sujeto mamifero. Se revelan metodos para la terapia de genes diana en el higado de mamifero, en su totalidad o en un solo lobulo hepatico. Los metodos revelados tratan sobre procedimientos basados en cateter minimamente invasores, en donde un organo diana es aislado y tratado localmente con un agente para la terapia genica. Los metodos ofrecen la transfeccion mas eficiente y localizada de tejido, y son adecuados para la terapia genica en sujetos humanos.
MX2007006524A 2004-12-01 2005-12-01 Metodos para el suministro dirigido de material genetico al higado. MX2007006524A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63235904P 2004-12-01 2004-12-01
PCT/US2005/043590 WO2006060641A2 (en) 2004-12-01 2005-12-01 Methods for targeted delivery of genetic material to the liver

Publications (1)

Publication Number Publication Date
MX2007006524A true MX2007006524A (es) 2007-06-22

Family

ID=36565758

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006524A MX2007006524A (es) 2004-12-01 2005-12-01 Metodos para el suministro dirigido de material genetico al higado.

Country Status (7)

Country Link
US (1) US20080025952A1 (es)
EP (1) EP1827502A4 (es)
JP (2) JP2008521575A (es)
CN (1) CN101068575A (es)
BR (1) BRPI0515819A (es)
MX (1) MX2007006524A (es)
WO (1) WO2006060641A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
PL2158319T4 (pl) 2007-05-11 2016-04-29 Alexion Pharma Inc Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie
AU2011245005A1 (en) 2010-04-30 2012-11-22 Alexion Pharma Holding Methods, compositions, and kits for the treatment of matrix mineralization disorders
US8738115B2 (en) * 2010-05-11 2014-05-27 Siemens Aktiengesellschaft Method and apparatus for selective internal radiation therapy planning and implementation
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN107982548A (zh) 2012-02-07 2018-05-04 全球生物疗法有限公司 核酸输送的区室化方法及其组合物和应用
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10898700B2 (en) 2012-10-26 2021-01-26 Urotronic, Inc. Balloon catheters for body lumens
WO2016172343A1 (en) * 2015-04-24 2016-10-27 Urotronic, Inc. Drug coated balloon catheters for nonvascular strictures
US10850076B2 (en) 2012-10-26 2020-12-01 Urotronic, Inc. Balloon catheters for body lumens
US11938287B2 (en) 2012-10-26 2024-03-26 Urotronic, Inc. Drug-coated balloon catheters for body lumens
WO2014066085A1 (en) 2012-10-26 2014-05-01 Lixiao Wang Drug coated balloon catheters for nonvascular strictures
US10881839B2 (en) 2012-10-26 2021-01-05 Urotronic, Inc. Drug-coated balloon catheters for body lumens
US10806830B2 (en) 2012-10-26 2020-10-20 Urotronic, Inc. Drug-coated balloon catheters for body lumens
US11504450B2 (en) 2012-10-26 2022-11-22 Urotronic, Inc. Drug-coated balloon catheters for body lumens
MX373332B (es) 2013-07-26 2020-05-21 Univ Iowa Res Found UNA PARTÍCULA rAAV Y UN AGENTE DE INMUNOSUPRESIÓN PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES.
US11364032B2 (en) 2013-08-08 2022-06-21 Global Bio Therapeutics, Inc. Clamp device for minimally invasive procedures and uses thereof
CA2920303C (en) 2013-08-08 2017-08-29 Global Bio Therapeutics, Inc. Injection device for minimally invasive procedures and uses thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
US11904072B2 (en) 2015-04-24 2024-02-20 Urotronic, Inc. Drug coated balloon catheters for nonvascular strictures
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
BR112019005553A2 (pt) * 2016-09-22 2019-06-11 All Vascular Pty Ltd dispositivos e métodos para hiperperfusão vascular do espaço extravascular
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
JP2021534111A (ja) 2018-08-10 2021-12-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
JP2021533805A (ja) * 2018-08-24 2021-12-09 スパーク セラピューティクス インコーポレイテッドSpark Therapeutics, Inc. 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法
CN109504709B (zh) * 2018-11-28 2020-07-24 上海安民生物技术有限公司 白蛋白启动子驱动的白蛋白表达载体
GB201900741D0 (en) * 2019-01-18 2019-03-06 Synpromics Ltd Liver-specifc inducible prometers and methods of use thereof
CN118454075A (zh) 2019-02-22 2024-08-09 优敦力公司 用于体腔的药物涂布的球囊导管
US12433938B2 (en) 2019-12-09 2025-10-07 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CN116096732A (zh) 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
AU2021376797B2 (en) * 2020-11-16 2025-05-01 Beijing Solobio Genetechnology Co., Ltd. Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof
AU2022218782A1 (en) 2021-02-12 2023-08-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CA3213123A1 (en) * 2021-03-25 2022-09-29 Robert L. Kruse Hydrodynamic gene delivery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5674192A (en) * 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US6265387B1 (en) * 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US6416510B1 (en) * 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6290689B1 (en) * 1999-10-22 2001-09-18 Corazón Technologies, Inc. Catheter devices and methods for their use in the treatment of calcified vascular occlusions
US6135976A (en) * 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
JP4426757B2 (ja) * 2000-11-03 2010-03-03 イノベータ リミテッド 核酸移送のための糖類と組み合わせたデキストリンポリマーを含む製剤
JP2004532822A (ja) * 2001-03-14 2004-10-28 アビジェン， インコーポレイテッド ビリオンの管逆行感染による組換えアデノ随伴ウイルス媒介遺伝子移入
US20040009151A1 (en) * 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
EP1532255A1 (en) * 2002-06-24 2005-05-25 Genzyme Corporation Methods of delivering gene therapy agents

Also Published As

Publication number Publication date
WO2006060641A3 (en) 2006-08-17
WO2006060641A2 (en) 2006-06-08
CN101068575A (zh) 2007-11-07
BRPI0515819A (pt) 2008-08-05
JP2012197297A (ja) 2012-10-18
US20080025952A1 (en) 2008-01-31
EP1827502A4 (en) 2008-01-16
JP2008521575A (ja) 2008-06-26
EP1827502A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
MX2007006524A (es) Metodos para el suministro dirigido de material genetico al higado.
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
WO2002020722A3 (en) Methods and compositions for in vitro targeting
EP4174179A3 (en) Rna containing modified nucleosides and methods of use thereof
IL160015A0 (en) Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2002051439A3 (en) Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
EP2465921A3 (en) Cardiac stem cells from biopsy
WO2008103993A3 (en) Compositions and methods for treating glycogen storage diseases
WO2005000245A3 (en) Compositions and methods for increasing telomerase activity
WO2005051315A3 (en) On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
SG166672A1 (en) Methods of down regulating target gene expression in vivo by introduction of interfering rna
WO2008031016A3 (en) Heterocyclic ligands for integrin imaging and therapy
WO2006014999A3 (en) Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
DK1526840T3 (da) Nanopartikler til DNA administration til et målorgan
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
WO2002012440A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
WO2006081158A3 (en) Predictive and therapeutic markers in overian cancer
WO2009067520A3 (en) Peptides specific for hepatocellular carcinoma cells and applications thereof
WO2007016501A3 (en) Compositions and method for brain specific targeted delivery of therapeutic agents
MX2022008412A (es) Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer.
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
WO2003070889A3 (en) Prostate specific genes and the use thereof in design or therapeutics
AU2002364501A1 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2005094236A9 (en) Activation of hypoxia-inducible gene expression